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Abstract Recent studies have demonstrated that the plasma
soluble receptor for advanced glycation end-products
(sRAGE) play a major role in developing macrovascular
complications of type 2 diabetes, including peripheral arterial
occlusion disease (PAOD). Cilostazol is an antiplatelet, an-
tithrombotic agent, which has been used for the treatment of
PAOD. We hypothesized that cilostazol attenuates the
severity of PAOD in patients with type 2 diabetes through the
augmentation of plasma sRAGE. Ninety type 2 diabetic pa-
tients with PAOD defined as intermittent claudication with
ankle-brachial index (ABI)^0.9 were recruited for an open-
labeled, placebo-controlled study for 52 weeks with oral
cilostazol 100 mg twice daily (n = 45) or placebo (n = 45).
Fasting plasma sRAGE, endothelial variables of E-selectin,
soluble vascular cell adhesion molecule-1 (sVCAM-1), and
inflammatory markers of high-sensitivity C-reactive protein
(hsCRP) and tumor necrosis factor-a (TNF-a) were deter-
mined. After completely the 52-week treatment program, the
ABI values were elevated in cilostazol group (P\ 0.001).
The plasma sRAGE was significantly increased (P = 0.007),
and hsCRP, sVCAM, and E-selectin concentrations were
significantly decreased (P = 0.028, \0.001 and \0.001,
respectively) with cilostazol treatment. In a partial correlation
analysis with adjustments for sex and age, the net change of
sRAGE significantly correlated with the change of ABI in the
cilostazol group (P = 0.043). In a stepwise multiple regres-
sion model, only the change with regards to sRAGE was
significantly associated with the change of ABI (P = 0.046).
Our results suggest that cilostazol may effectively attenuate
the severity of PAOD in patients with type 2 diabetes. Plasma
sRAGEplays a role as an independent predictor for improving
the index of PAOD.
Keywords Cilostazol  Peripheral arterial occlusion
disease  Soluble receptor for advanced glycation end
product
Introduction
The prevalence of type 2 diabetes is rising at an alarming rate
worldwide and has become a leading cause of morbidity and
mortality associated with accelerated atherosclerosis, includ-
ing coronary artery, cerebrovascular, and peripheral arterial
occlusive disease (PAOD) [1].Recent studiesdemonstrate that
PAOD correlates strongly with the risk of major cardiovas-
cular events and has a high prevalence of coexistent coronary
and cerebrovascular disease, especially in type 2 diabetes [2].
Because the prevalence of PAOD also increases progressively
with age, PAOD is a growing clinical problem due to the
increasingly aged population worldwide [3].
In addition to the established cardiovascular risk factors,
recent studies reported reduced plasma circulating levels of
receptor for advanced glycation end-products (sRAGE) as
an important novel biomarker in hypertension, type 2
diabetes, vascular dementia, and in non-diabetic subjects
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with coronary artery disease [4–9]. One recent study also
demonstrated that patients combined with coronary artery
disease and PAOD have lower sRAGE levels than patients
with coronary artery disease alone [10]. RAGE has a
C-truncated secreted isoform, termed soluble RAGE
(sRAGE). RAGE is a multiligand receptor that engages
diverse ligands relevant to the atherogenesis of
atherosclerosis [11]. However, vascular endothelial cells
exposed to a variety of RAGE ligands augments the RAGE
activation to result in enhanced generation of reactive
oxygen species and in the activation of the transcription
factor and nuclear factor kB (NF-kB). This leads to sus-
tained upregulation of proinflammatory mediators, adhe-
sion molecules, and to an initiation of atherosclerosis [12].
Cilostazol is an antiplatelet, antithrombotic agent that
has been used for the treatment of chronic PAOD and for
the secondary prevention of brain infarction [13]. Cilosta-
zol not only inhibits platelet activation but also increases
vasodilatation [14]. In addition, it has been shown to inhibit
vascular smooth muscle cell proliferation, then improve
peripheral blood flow and insulin sensitivities via attenua-
tion of inflammation process [15, 16]. Given that the anti-
atherogenic effect of cilostazol is ascribed to its property to
suppress superoxide and TNF-a formation, and thereby
reduces NF-kB activation and transcription, vascular cell
adhesion molecule/monocyte chemotactic protein-1
(VCAM/MCP-1) expressions, and monocyte recruitments
in low-density lipoprotein (LDL) receptor-null mice [17]; it
remains unclear as to whether cilostazol improves the
severity of PAOD via the pathway of RAGE to influence
downstream signals such as inflammation and adhesion
molecules [18]. Accordingly, the purpose of this study was
designed as an open, placebo-controlled study evaluating
cilostazol in patients with type 2 diabetes plus PAOD. We
will test the hypothesis that cilostazol may ameliorate the
severity of PAOD in patients with type 2 diabetes via the
augmentation of plasma circulating RAGE.
Materials and methods
Subjects and study design
An open, placebo-controlled study was conducted. The
study protocol was approved by institutional review
boards. All subjects provided written informed consent to
participate in the study prior to the initiation of the study.
The study enrolled subjects 35–80 years of age with type 2
diabetes that had been first diagnosed with this disease after
being 30 years of age. Patients with type 2 diabetes plus
PAOD were selected to participate in this study to evaluate
the ankle-brachial index (ABI), inflammation markers, and
subjective improvement effects using oral cilostazol
100 mg twice daily or placebo for the 52-week treatment
period. PAOD was documented with ABI of ^0.9 in the
reference leg when the pressures are taken by pulses value
record in a supine position. Other inclusion criteria were as
follows: type 2 diabetes with A1c 7.0–12 % with stable
medication condition prior to 3 months and dyslipidemia
or hypertension with stable medication condition prior to
3 months.
Intermittent claudication was ascertained using a stan-
dardized physician-administered questionnaire. The speci-
fic questions were leg discomfort on exertion that was
related to ground steepness or rapidity of walking that was
relieved with rest. Participants were questioned with re-
gards to cigarette smoking habit at each examination.
Subjects were excluded from the study if they had type 1
diabetes mellitus; females of childbearing potential (Pa-
tients who have been surgically sterilized bilateral tubal
ligation or hysterectomy or who are at least 1 year post-
menopausal may participate in the study) or females of
lactating; patients who had a history of heart failure, my-
ocardial infraction, coronary vascular disease, or unstable
angina pectoris within recent 6 months; chronic kidney
failure (on dialysis any kind, kidney implantation); any
history within the previous year of clinically significant
bleeding tendencies, hemorrhagic tendencies; malignancy
of any kind; use of an investigational drug within the past
3 months; had impaired liver function (aspartate amino-
transferase and/or alanine aminotransferase[2 times the
upper limit of reference range); or had any uncontrolled or
untreated systemic disease considered by the investigator
to make them unfit to enter the study.
Ninety eligible subjects were enrolled and visited the
investigator four times with 12-week intervals for further
efficacy and safety assessment, and the time schedule was
set on the following date during the study. The primary
efficacy end point was changes with regards to ABI and
sRAGE after 52-week treatment. The secondary efficacy
parameters were the changes in A1c, blood pressure, and
lipid profile concentrations over the treatment period from
baseline to the end of the study. In addition, changes in
plasma inflammatory markers of TNF-a and hsCRP, en-
dothelial markers of E-selectin, soluble intercellular adhe-
sion molecule-1 (sICAM-1), and sVCAM-1 were also
measured.
Laboratory measurements
After maintaining a 10 h fasting state, blood samples were
obtained from each participant to determine plasma glu-
cose, A1c, creatinine, and lipid profiles. Plasma circulating
hsCRP, tumor TNF-a, E-selectin, sICAM-1, and sVCAM-1
were subsequently measured. Serum total cholesterol,
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triglyceride, and low-density lipoprotein cholesterol (LDL-
C) were measured using the dry, multilayer analytical slide
method in the Fuji Dri-Chem 3000 analyzer (Fuji Photo
Film Corporation, Tokyo, Japan). The levels of A1c were
evaluated by ion-exchange high-pressure liquid chro-
matography (HPLC) method (BIO-RAD VARIANT II, Los
Angeles, CA, USA). Plasma glucose concentrations were
determined by the glucose oxidase method on a Beckman
Glucose Analyzer II (Beckman Instruments, Fullerton, CA,
USA).
Plasma hsCRP levels were measured using the Tina-
quant (Latex) high-sensitivity assay (Roche, Mannheim,
Germany). The intra-assay and inter-assay CV for hsCRP
were 3.7 and 4.9 %, respectively. Serum TNF-a was
measured with the BiotrakTM high-sensitivity human
ELISA kit from Amersham Biosciences (Bucking-
hamshire, UK). The intra-assay and inter-assay CV for
TNF-a were 3.5 and 5.3 %, respectively. Levels of
E-selectin, sICAM-1, and sVCAM-1 were measured by
commercial ELISA (R&D Systems, Minneapolis, USA).
The intra-assay and inter-assay CV for E-selectin were
4.5 and 6.2 %; sICAM-1 were 3.5 and 7.1 %; sVCAM-1
were 5.0 and 8.7 %.
Serum sRAGE levels were determined using ELISA
(Quantikine; R & D systems, Minneapolis, MN, USA)
according to the manufacturer’s protocol. Briefly, a
monoclonal antibody raised against the N-terminal extra-
cellular domain of human RAGE consisting of amino acids
Gln 24 through Ala 344 was used to capture sRAGE from
serum. Captured sRAGE was detected with a polyclonal
antihuman sRAGE antibody. After washing, plates were
incubated with streptavidin horseradish peroxidase, devel-
oped with appropriate substrate and OD450 was deter-
mined using an ELISA plate reader. The intra- and inter-
assay CV were 2.1 and 5.9 %, respectively. All of the
concentrations for the above biochemical variables were
determined in duplicate and the values of the two samples
were averaged.
Measurement of ABI
The ABI measurement of our study has been descripted
previously [18]. Briefly, measurement of upper- and lower-
extremity blood pressure was performed in a supine posi-
tion after at least 30 min of rest. The blood pressure cuffs
were placed over each brachial artery and above each
malleolus. To calculate the ABI ratio, the average systolic
blood pressure measurement in the ankle was divided by
the average systolic blood pressure measurement in the
arm. The mean pressure of the higher arm was used to
calculate the ABI separately for each leg. An ABI greater
than 1.5 was excluded.
Statistical analysis
Arithmetic means and standard deviations (SD) were cal-
culated for the variables measured at least on an interval
scale. Efficacy end points of this study include ABI and
sRAGE after treatment, subjective improvement scale, and
inflammation or endothelial markers. Categorical variables
were analyzed by the v2test. Continuous variables were
tested for normal distribution by the Kolmogorov–Smirnov
test. Statistically significant differences between the basal
and treatment values within the groups were analyzed with
Student’s t test. Mann–Whitney U test was tested for non-
parametric method if necessary. Partial correlation analysis
adjusting for age and sex was used to assess the correlation
between the change of ABI and other variables on cilostazol
treatment. Stepwise multiple linear regression analysis, with
the changes of ABI as dependent variables, was used to study
the association and independent determinants of covariates.
A P value of less than 0.05 was considered to be statistically
significant. All statistical analyses were performed using
SPSS Inc. 16.0 software (SPSS, Chicago, IL, USA). The
number of patients reporting side effects during the different
treatments was recorded. In general, the incidence of side
effects was low, and only a descriptive method was used.
Results
Of the 156 subjects from the Division of Endocrinology and
Metabolism of the Tri-Service General Hospital in Taipei,
Taiwan, assessed for eligibility, 90 subjects satisfied the in-
clusion criteria and were assigned to treatment with 1:1
randomization (Fig. 1). Forty-four of 45 subjects in the
156 subjects were 
registered
66 subjects were 
excluded by criteria
90 subjects were 
enrolled
44 subjects completed 
assessments based on 
pre-protocol population
43 subjects completed 
assessments based on 
pre-protocol population
45 subjects were 
assigned to placebo
treatment
45 subjects were 
assigned to cilostazol 
treatment
2 dropped out
2 adverse events 
1 dropped out
1 loss follow-up
Fig. 1 Flow diagram of our study
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placebo group and 43 of 45 subjects in the cilostazol group
took the study medication for at least 52 weeks with a
compliance rate of[80 %. Due to an adverse event of severe
dizziness, two subjects in the cilostazol group were with-
drawn from treatment. In addition, one subject in the placebo
group was lost to follow-up. No occurrence of serious ad-
verse events, including death, danger to life, disability, or
hospitalization (initial or prolonged) requiring intervention
to prevent permanent impairment or damage, was observed
during the study period.
There were no significant differences between both
groups related to demographic and baseline characteristics
as detailed in Table 1. After the completion of the 52-week
treatment period, the ABI value was significantly elevated
(0.84 ± 0.09 vs 0.89 ± 0.11, P\ 0.001) and HbA1c level
was reduced (8.1 ± 1.3 vs 7.6 ± 1.4 %, P = 0.002) in the
cilostazol group without significant alteration in the
placebo group. However, increases in total cholesterol,
LDL-cholesterol, and creatinine levels were demonstrated
in the placebo group, but these were not found in the
cilostazol group. No differences after treatment in terms of
body mass index, blood pressure, fasting glucose, and
triglyceride were observed in both groups.
The levels of plasma sRAGEwere significantly increased
(1234.1 ± 822.5 vs 1510.0 ± 1215.7 pg/ml, P = 0.007)
and hsCRP (3.0 ± 3.2 vs 1.9 ± 2.1 mg/L, P = 0.028),
sVCAM (205.1 ± 113.7 vs 172.7 ± 101.2 ng/ml, P\
0.001), and E-selectin concentrations (29.1 ± 23.0 vs
23.4 ± 18.5 ng/ml,P\ 0.001)were significantly decreased
with cilostazol treatment in Fig. 2. No statistically sig-
nificant differences in terms of TNF-a and sICAM were
shown after treatment in both groups. In Spearman partial
correlation analysis with adjusting for sex and age, only net
changes of sRAGE were significantly correlated with chan-
ges of ABI in cilostazol group (r = 0.385, P = 0.043)
(Table 2). By stepwise multiple regression analysis, only
changes of sRAGE was determined to be an independent
predictor of changes of ABI (b = 0.367, P = 0.046) as
documented in Table 3.
Discussion
The influence of plasma AGE/sRAGE levels, inflammation
markers, and adhesion molecules on cilostazol therapy,
particularly in humans, remains unclear. The main finding
of present study demonstrates that cilostazol effectively
improves the severity of PAOD, defined as the index of
ABI in patients with type 2 diabetes via an augmentation of
plasma circulating sRAGE and an attenuation of proin-
flammatory markers, subsequently affecting the adhesion
molecules regulation. The enhancement of plasma sRAGE
plays a role as an independent determinant for improving
the severity of peripheral arterial insufficiency.
Cilostazol, a phosphodiesterase III (PDE III) inhibitor,
decreases the activity of PDE III, and then accumulation of
Table 1 Baseline demographic data and clinical characteristics of
the study groups
Placebo (n = 44) Cilostazol (n = 43) P value
Age (year) 65.6 ± 7.8 67.1 ± 9.3 NS
Sex (M %) 30.2 36.2 NS
Body mass index (kg/m2)
Before 26.8 ± 4.4 27.3 ± 4.5 NS
After 26.6 ± 4.4 27.0 ± 4.5
P value NS NS
Systolic pressure (mmHg)
Before 135.4 ± 18.0 138.0 ± 14.3 NS
After 132.7 ± 17.7 137.2 ± 12.8
P value NS NS
Diastolic pressure (mmHg)
Before 80.5 ± 9.0 80.4 ± 8.7 NS
After 80.1 ± 9.5 80.9 ± 7.3
P value NS NS
Fasting glucose (mg/dl)
Before 141.7 ± 29.6 139.7 ± 44.8 NS
After 155.0 ± 57.6 138.4 ± 48.5
P value NS NS
HbA1c (%)
Before 8.3 ± 1.1 8.1 ± 1.3 NS
After 8.1 ± 1.0 7.6 ± 1.4
P value NS 0.002
Total Cholesterol (mg/dl)
Before 182.1 ± 35.7 177.7 ± 33.1 NS
After 192.5 ± 35.8 186.4 ± 41.0
P value 0.022 NS
LDL-C (mg/dl)
Before 109.6 ± 28.1 108.4 ± 33.6 NS
After 115.9 ± 28.0 114.5 ± 30.3
P value 0.046 NS
Triglyceride (mg/dl)
Before 153.6 ± 69.4 161.7 ± 74.4 NS
After 161.0 ± 82.3 157.1 ± 91.0
P value NS NS
Creatinine (mg/dl)
Before 1.02 ± 0.31 0.96 ± 0.33 NS
After 1.11 ± 0.35 1.01 ± 0.41
P value 0.009 NS
ABI (affected limb)
Before 0.84 ± 0.06 0.84 ± 0.09 NS
After 0.83 ± 0.07 0.89 ± 0.11
P value NS <0.001
Bold values indicate statistical significance
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30-50 cyclic adenosinemonophosphate (cAMP) levels occurred
in the platelets, smooth muscle cells, as well as decreases
intracellular calcium which leading to cellular relaxation.
Cilostazol has antiplatelet effects, has a vasodilator effect on
smooth muscle cells and anti-proliferative activity on smooth
























































Fig. 2 Comparing with placebo, levels of plasma sRAGE were
significantly increased and hsCRP, sVCAM and E-selectin concen-
trations were significantly decreased at the end of 52 weeks with
cilostazol treatment. Data were expressed as mean ± SD. Statistical
analysis was conducted with the Mann–Whitney U test. sRAGE
soluble receptor for advanced glycation end-products, TNF-a tumor
necrosis factor-a, hsCRP high-sensitive C-reactive protein, sICAM-1
soluble intercellular adhesion molecule-1, and sVCAM-1 soluble
vascular cell adhesion molecule-1
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cilostazol suppresses cytokine production in a mastocyte
culture [19]. It also blocks the production and expression of
MCP-1 induced by TNF-a, and inhibits VCAM-1 via sup-
pression of the nuclear transcription factor kappa B (NF-kB)
in culture of endothelial cells taken from a human umbilical
cord [20].The ligandofAGEsbinding to the receptor ofAGEs
activates the inflammatory process leading to an over-ex-
pression of downstream signals such as VCAM-1, ICAM-1,
and E-selectin on cultured human endothelial cells [21]. This
is combined with a higher expression of the mRNA for the
respective adhesionmolecules [22]. This result implicates that
the combination of matrix glycation and inflammation up-
regulates the activation of the endothelial cell adhesion cas-
cade. Exposure of human endothelial cells to glycated albu-
min leads to an increase in human monocyte adhesion to
endothelium and an induction of both soluble and cell-asso-
ciated expression of VCAM-1, ICAM-1, and E-selectin.
Therewas alsoanaugmentation in the levels of thesemolecule
transcripts and an increase in the DNA binding activity for
NF-kB in the promoters of these antigens observed [23].
Animal studies also demonstrated that sRAGE have
been proved to be benefit in decreasing atherosclerosis in
diabetic mice [24, 25]. Recent study has revealed negative
correlations between levels of sRAGE and coronary heart
disease in diabetes [26]. Hence, we speculated that
cilostazol inhibits the signaling of NF-kB and decreases
transcription of different proteins, including ICAM-1,
VCAM-1, E-selectin, TNF-a, interleukin-6 (IL-6), AGE,
and ligands for RAGE in human atherosclerosis. Mean-
while, using in vitro studies (unpublished data), we pro-
vided evidence that cilostazol decreased RAGE, VCAM-1,
and ICAM-1 expression and might be through inhibiting
RAGE/ERK/NF-jB pathway. Less circulation sRAGE
serves as a scavenger receptor for decreasing serum AGEs
and other RAGE ligands. As a result, increasing concen-
trations of sRAGE, as well as decreasing levels of
E-selectin and sVCAM may occur in diabetic subjects with
cilostazol treatment [21, 27, 28]. Moreover, subsequent
suppression of CRP production was also displayed via
degradation of cytokines such as IL-6 and TNF-a in
hepatocytes [29, 30].
Another clinical effect of cilostazol is the modification
of lipid profiles, including reducing the concentrations of
chylomicrons, remaining very low-density lipoprotein
(VLDL), triglycerides as well as increasing HDL in pa-
tients with PAOD [31–35]. However, these beneficial ef-
fects of lipids were not observed significantly but only a
mild improvement in our study. Besides, our study did not
control for dyslipidemia, concomitant use of lipid-
modifying agents, diet, poor diabetes control, or other
factors that may influence serum lipids prospectively.
The metabolic parameters changed in both the cilostazol
and placebo groups, especially decreased HbA1c level in
cilostazol groups. Better glycemic control was found in the
cilostazol group probably through the reduction of insulin
resistance by reducing inflammation [16]. The same results
were also observed in other animal studies [36, 37].
Although there were elevations observed in other lipid
profile and chemical tests in the cilostazol group, namely
total cholesterol, LDL-C, and creatinine, the increases were
small and the results did not reach a level of statistical
significance, including a comparison to the placebo group.
There were a number of limitations in this study that are
worth highlighting. First, our study did not demonstrate a
causal relationship between the severity of PAOD and
circulating sRAGE, but only showed their association with
one another. Second, ABI measurement only provides us
with a simple tool to define the severity of peripheral ar-
terial insufficiency. Angiography or magnetic resonance
angiography may be more precise. Furthermore, non-in-
vasive transcutaneous oxygen tension (TcPO2) had better
predictive value than that of ABI, in predicting cardio-
vascular events and evaluating PAOD [38].
Table 2 Spearman partial correlation coefficients between the
changes of ankle-brachial index and the differences in variables with





Fasting glucose -0.127 0.518
HbA1c 0.160 0.416
LDL-C -0.116 0.556









Corrected for age and sex. Bold value indicates statistical significance
Table 3 Stepwise multiple linear regression analysis with the change
of ankle-brachial index as the dependent variable
Unstandardized coefficients Standardized coefficients
Variables B SE b t P value
Constant 0.051 0.015 3.412 0.002
sRAGE 5.012E-5 0.001 0.367 2.090 0.046
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In summary, our results suggest that that cilostazol may
effectively attenuate the severity of PAOD in patients with
type 2 diabetes. Plasma sRAGE plays a role as an inde-
pendent determinant for improving the index of peripheral
arterial insufficiency.
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